Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices

por Muldur, Sinan, Vadysirisack, Douangsone D., Ragunathan, Sharan, Tang, Yalan, Ricardo, Alonso, Sayegh, Camil Elie, Irimia, Daniel
Publicado 2021

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity

por Fichtner, Miriam L., Hoarty, Michelle D., Vadysirisack, Douangsone D., Munro-Sheldon, Bailey, Nowak, Richard J., O’Connor, Kevin C.
Publicado 2022

Prevention of Anti-HMGCR Immune-Mediated Necrotising Myopathy by C5 Complement Inhibition in a Humanised Mouse Model

por Julien, Sarah, Vadysirisack, Douangsone, Sayegh, Camil, Ragunathan, Sharan, Tang, Yalan, Briand, Emma, Carrette, Marion, Jean, Laetitia, Zoubairi, Rachid, Gondé, Henri, Benveniste, Olivier, Allenbach, Yves, Drouot, Laurent, Boyer, Olivier
Publicado 2022

Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis

por Obaid, Abeer H., Zografou, Chryssa, Vadysirisack, Douangsone D., Munro-Sheldon, Bailey, Fichtner, Miriam L., Roy, Bhaskar, Philbrick, William M., Bennett, Jeffrey L., Nowak, Richard J., O'Connor, Kevin C.
Publicado 2022

A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity

por Qiao, Shuxi, Dennis, Michael, Song, Xiufeng, Vadysirisack, Douangsone D., Salunke, Devika, Nash, Zachary, Yang, Zhifen, Liesa, Marc, Yoshioka, Jun, Matsuzawa, Shu-Ichi, Shirihai, Orian S., Lee, Richard T., Reed, John C., Ellisen, Leif W.
Publicado 2015

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

por Tang, Guo-Qing, Tang, Yalan, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Ma, Zhong, Zhu, Nanqun, Wang, Jian-Guo, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso
Publicado 2023

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

por Tang, Guo-Qing, Tang, Yalan, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Ma, Zhong, Zhu, Nanqun, Wang, Jian-Guo, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso
Publicado 2023